Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON33361
NL-OMON33361
Completed
N/A

Tailored treatment of prostate cancer by biomarkers: PROCABIO - PROCABIO

Erasmus MC, Universitair Medisch Centrum Rotterdam0 sites50 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsprostate cancerProstate carcinoma1003858810036958

Overview

Phase
N/A
Intervention
Not specified
Conditions
prostate cancer
Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Enrollment
50
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Patients who decide to participate in PRIAS or are participating in PRIAS for less than 2 years are eligible. The inclusion criteria for PRIAS are the following:
  • •1\. Histologically proven adenocarcinoma of the prostate
  • •2\. Men should be fit for curative treatment
  • •3\. PSA\-level at diagnosis \<\= 10 ng/mL
  • •4\. PSA density (PSA D) less than 0,2
  • •5\. Clinical stage T1C or T2
  • •6\. Adequate biopsy sampling (see 'biopsy protocol')
  • •7\. Gleason score 3\+3\=6
  • •8\. One or 2 biopsy cores invaded with prostate cancer
  • •9\. Participants must be willing to attend the follow\-up visits

Exclusion Criteria

  • •The exclusion criteria for PRIAS are the following:
  • •1\. Men who can not or do not want to be irradiated or operated
  • •2\. A former therapy for prostate cancer

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
N/A
Clinical study of prostate cancer dagnositic makers using genetic polymorphismsProstate cancer
JPRN-UMIN000019278Kyoto University2,000
Completed
N/A
Improving cancer targeting accuracy in prostate radiotherapy with SeedTracker real-time image guidance system- A Phase I studyProstate CancerCancer - Prostate
ACTRN12618001421224iverpool Hospital Cancer Therapy30
Recruiting
Phase 2
Primary focal therapy for prostate cancer using low-dose-rate brachytherapyprostate cancer
JPRN-UMIN000050997Saitama Cancer Center200
Recruiting
N/A
Personalizing therapy of urogenital cancer by metastatic tissue Immune profiling, Organoid culture, and NExt genERation sequencingUrigenital cancerbladder cancer and prostate cancer10038364
NL-OMON46194Radboud Universitair Medisch Centrum150
Recruiting
Phase 2
Salvage focal therapy for prostate cancer using low-dose-rate brachytherapyprostate cancer
JPRN-UMIN000051113Saitama Cancer Center100